Cel Sci (CVM) Depreciation & Amortization (CF) (2010 - 2026)
Cel Sci (CVM) posted Depreciation & Amortization (CF) of $948000.0 for Q1 2026, down 1.7% sequentially from $964422.0 in Q4 2025, and down 1.15% YoY from $959000.0 in Q1 2025.
Cel Sci (CVM) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Cel Sci has reported Depreciation & Amortization (CF) for 17 years, with the latest figure at $948000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 1.15% year-over-year to $948000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (down 2.49% YoY) and the FY2025 annual result came in at $3.9 million, down 2.12% from the prior year.
- Depreciation & Amortization (CF) eased to $948000.0 in Q1 2026 per CVM's latest filing, from $964422.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $1.0 million in Q4 2023 and troughed at $948000.0 in Q1 2026.
- A 5-year average of $979704.5 and a median of $984208.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) soared 78.54% in 2022, then decreased 3.1% in 2025.
- Over 5 years, Depreciation & Amortization (CF) stood at $988543.0 in 2022, then rose by 1.63% to $1.0 million in 2023, then retreated by 0.94% to $995192.0 in 2024, then fell by 3.09% to $964422.0 in 2025, then dropped by 1.7% to $948000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $948000.0, $964422.0, and $960850.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | 939,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 948,000.00 |
| Mar 31, 2026 | 948,000.00 |
| Dec 31, 2025 | 964,422.00 |
| Dec 31, 2025 | 964,422.00 |
| Sep 30, 2025 | 960,850.00 |
| Sep 30, 2025 | 960,850.00 |
| Jun 30, 2025 | 959,009.00 |
| Jun 30, 2025 | 959,009.00 |
| Mar 31, 2025 | 959,000.00 |
| Mar 31, 2025 | 959,000.00 |
| Dec 31, 2024 | 995,192.00 |
| Dec 31, 2024 | 995,192.00 |
| Sep 30, 2024 | 991,580.00 |
| Sep 30, 2024 | 991,580.00 |
| Jun 30, 2024 | 984,208.00 |
| Jun 30, 2024 | 984,208.00 |
| Mar 31, 2024 | 988,762.00 |
| Mar 31, 2024 | 988,762.00 |
| Dec 31, 2023 | 1.00 Mn |
| Dec 31, 2023 | 1.00 Mn |